ClinicalTrials.gg
Active, not recruitingNCT03712202Updated Oct 29, 2026Results posted

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

A Phase 2 interventional study of Bleomycin and Brentuximab Vedotin in Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma and Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, sponsored by City of Hope Medical Center. Active, not recruiting at 17 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know · 13 judgments

Updated Oct 29, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
12th of 80
159 · median 52
Started
2018
with 4 others
Phase 2
41 of 80
8 open now
Primary completion
2024-11
later than 8 of 27 live
Registered
60th of 80
by date
Lead sponsor
7 of 80
City of Hope Medical Center

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 12th largest by enrollment, is one of 5 that started in 2018, is one of 41 in phase 2, reaches primary completion later than 8 of the 27 other live ones, and was the 60th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine the 18-month progression free survival (PFS) for each arm of therapy stratified by positron emission tomography (PET)/computed tomography (CT)-2 response.

SECONDARY OBJECTIVES:

I. Assess safety, tolerability, and quality of life (QOL) for each arm of therapy.

II. Measure PET/CT-2 negativity rate after 2 lead-in cycles of standard of care doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD).

III. Evaluate the 3-year PFS and overall survival (OS) for each arm of treatment.

EXPLORATORY OBJECTIVES:

I. Evaluate if a baseline antitumor immune response, as assessed by a Nanostring gene panel, correlates with PFS.

II. Evaluate if minimal residual disease (MRD) status, as monitored by cancer personalized profiling by deep sequencing (CAPP-Seq) of circulating tumor (ct) deoxyribonucleic acid (DNA), can be correlated with PFS.

OUTLINE: Patients are assigned to 1 of 2 groups based on their PET/CT-2 scans.

GROUP I (PET/CT-2 NEGATIVE): Patients without bulky disease are randomized to either Arm A or B and patients with bulky disease are assigned to Arm B.

ARM A: Patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

GROUP II (PET/CT-2 POSITIVE): Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 3 years.

03

Conditions studied

  • Ann Arbor Stage I Hodgkin Lymphoma
  • Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma
  • Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma
  • Ann Arbor Stage IA Hodgkin Lymphoma
  • Ann Arbor Stage IB Hodgkin Lymphoma
  • Ann Arbor Stage II Hodgkin Lymphoma
  • Ann Arbor Stage IIA Hodgkin Lymphoma
  • Ann Arbor Stage IIB Hodgkin Lymphoma
  • Classic Hodgkin Lymphoma
  • Lymphocyte-Rich Classic Hodgkin Lymphoma
  • Ann Arbor Stage I Lymphocyte-Depleted Classic HL
  • Ann Arbor Stage II Lymphocyte-Depleted Classic HL
  • Ann Arbor Stage II Mixed Cellularity Classic HL
  • Ann Arbor Stage II Nodular Sclerosis Classic HL

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines.
  • (ECOG) =\< 2.
  • confirmed diagnosis of classical Hodgkin lymphoma (cHL) by current World Health Organization classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, or classical Hodgkin lymphoma, NOS [not otherwise specified]) at local enrolling center. Nodular lymphocyte-predominant Hodgkin lymphoma is excluded
  • Stage IA, IB, IIA, or IIB cHL by Cotswold modified Ann Arbor staging done prior to any treatment with ABVD.
  • Must have prior to standard of care ABVD treatment at least one lesion that is > 1.5 cm in the longest diameter on cross-sectional imaging and measureable in two perpendicular dimensions on CT and fludeoxyglucose (FDG) avid by PET.

Exclusion criteria

Exclusion Criteria:

  • Patients must be naive in terms of any prior therapy for Hodgkin lymphoma (including immunotherapy, chemotherapy or radiation therapy) with the exception that they may have received up to 2 cycles of ABVD as standard of care therapy prior to enrollment, as long as they can start protocol therapy (therapy administered in Arms A, B1/B2, or C) within timelines specified by the trial.
  • Peripheral sensory neuropathy > grade 1 or any peripheral motor neuropathy.
  • History of another primary that has not been in remission for at least 3 years. (The following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on or a squamous intraepithelial lesion on Papanicolau [PAP] smear)
  • Known cerebral/meningeal disease.
  • History of progressive multifocal leukoencephalopathy (PML).
  • Known history of pancreatitis.
  • Documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction, or cardiac symptoms consistent with class III-IV within 6 months prior to enrollment
  • Uncontrolled cardiac disease including ventricular dysfunction, \< 45%, coronary artery disease, or arrhythmias.
  • Known to recombinant proteins, murine proteins, or to any contained in the drug formulation of brentuximab vedotin, nivolumab, or any component of ABVD.
  • Known active infection with or . Patients who are hepatitis B carriers can enroll if have a negative hepatitis B polymerase chain reaction (PCR) DNA test and are on hepatitis B suppressive medication management with entecavir or lamivudine. Patients with past active hepatitis C virus (HCV) infection are eligible if they are PCR negative after curative therapy. Testing to be done only in patients suspected of having infections or exposures.
  • Known active infection with (HIV). Patients who are HIV positive can enroll if is > 200/uL and have an undetectable or unquantifiable HIV viral load within 28 days of enrollment, have concurrent management with infectious disease specialists, and are on stable combination antiretroviral therapy. Participants are required to be on antiretroviral regimens that are in accordance with the current International acquired immune deficiency syndrome (AIDS) Society guidelines concurrently with chemotherapy. The specific agents are at the discretion of the Investigator and the use of agents currently available on an expanded access basis is allowed. Use of experimental antiretroviral agents or those containing zidovudine (including Combivir and Trizivir) or ritonavir (includes Norvir or Kaletra), Cobicistat, Didanosine (Videx or Videx EC), or similar potent CYP3 inhibitors are prohibited. In order to be eligible, participants taking zidovudine or ritonavir, Cobicistat, Didanosine, or other CYP3 inhibitors must change to a different regimen 7 days prior to therapy initiation. Changes to highly active antiretroviral therapy (HAART) therapy during the study may be made if medically necessary (toxicity, failure of regimen, etc.). Participants must be on HAART for at least 7 days prior to therapy. HIV testing to be done only in patients suspected of having infections or exposures
  • Subjects with active interstitial pneumonitis.
  • Subjects with active, known or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
  • Females only: pregnant or breastfeeding.
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Arm A (brentuximab vedotin, nivolumab)

    Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Brentuximab Vedotin · Biological: Nivolumab · Other: Quality-of-Life Assessment

  • Experimental
    Arm B1 (ABVD, nivolumab) for non-bulky patients

    Patients receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Bleomycin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine

  • Experimental
    Arm B2 (ABVD, nivolumab) for bulky patients

    Patients with bulky diseases at diagnosis receive doxorubicin IV, bleomycin IV, vinblastine IV, dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Bleomycin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine

  • Experimental
    Arm C (AVD, brentuximab vedotin, nivolumab)

    Patients receive doxorubicin IV, vinblastine IV, dacarbazine, IV and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients that are PET/CT negative receive nivolumab IV over 60 minutes on day 1. Treatment with nivolumab repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Other: Quality-of-Life Assessment · Drug: Vinblastine

Interventions

  • Given IV

    Also known as: BLEO, BLM

  • Given IV

    Also known as: ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35

  • Given IV

    Also known as: 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007

  • Given IV

    Also known as: Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • Given IV

    Also known as: Vincaleucoblastine, VLB

06

What researchers measure

Primary outcomes

  1. 18-month Progression-free Survival (PFS) for Each Arm of Therapy

    Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.

    Time frame: Up to 18 months

Secondary outcomes

  1. Number of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment

    Toxicities were recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The events are possible, probable, or definite attribution to the study treatment.

    Time frame: Up to 4 years

  2. 2-year Progression-free Survival (PFS) for Each Arm of Therapy

    Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.

    Time frame: Up to 2 years

07

Results

Posted Oct 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
Started45363537
Completed38283029
Not completed7858
Withdrew: Adverse event4431
Withdrew: Physician decision1221
Withdrew: Withdrawal by subject1102
Withdrew: Progression0002
Withdrew: Due to partial response0002
Withdrew: Participant wished to pursue radiation therapy instead0100
Withdrew: Lost to follow-up1000

Outcome measures

Primary18-month Progression-free Survival (PFS) for Each Arm of Therapy

Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.

Time frame:
Up to 18 months
Reported as:
Number · percentage of participants
18-month Progression-free Survival (PFS) for Each Arm of Therapy
percentage of participantsArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
18-month Progression-free Survival (PFS) for Each Arm of Therapy100 (NA to NA)100 (NA to NA)97 (81 to 100)85 (68 to 94)
SecondaryNumber of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment

Toxicities were recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The events are possible, probable, or definite attribution to the study treatment.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment
ParticipantsArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
Number of Patients Experiencing Grade 3-5 Adverse Events Related to Study Treatment015131
Secondary2-year Progression-free Survival (PFS) for Each Arm of Therapy

Progression-free survival (PFS) was estimated using the Kaplan-Meier product-limit method along with the Greenwood estimator of standard error; 95% confidence interval for the survival timepoint estimates was constructed based on the log-log transformation.

Time frame:
Up to 2 years
Reported as:
Number · percentage of participants
2-year Progression-free Survival (PFS) for Each Arm of Therapy
percentage of participantsArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
2-year Progression-free Survival (PFS) for Each Arm of Therapy100 (NA to NA)100 (NA to NA)86 (67 to 95)77 (57 to 89)

Adverse events

Collected over From initiation of treatment through the end of protocol, up to 4 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Brentuximab Vedotin, Nivolumab)0/45 (0%)7/45 (15.6%)41/45 (91.1%)
Arm B1 (ABVD, Nivolumab) for Non-bulky Patients0/36 (0%)5/36 (13.9%)36/36 (100%)
Arm B2 (ABVD, Nivolumab) for Bulky Patients0/35 (0%)4/35 (11.4%)35/35 (100%)
Arm C (AVD, Brentuximab Vedotin, Nivolumab)0/37 (0%)9/37 (24.3%)37/37 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
FEVERGeneral disorders1/451/360/354/37
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/451/363/353/37
COVID-19Infections and infestations0/450/360/352/37
RASH MACULO-PAPULARSkin and subcutaneous tissue disorders2/450/360/350/37
NON-CARDIAC CHEST PAINGeneral disorders0/450/361/350/37
DEVICE RELATED INFECTIONInfections and infestations0/450/361/350/37
DIARRHEAGastrointestinal disorders0/451/360/350/37
INFLUENZAInfections and infestations0/451/360/350/37
INFLUENZA AInfections and infestations0/451/360/350/37
VASCULAR ACCESS COMPLICATIONInjury, poisoning and procedural complications0/451/360/350/37
Most frequent other events
Showing 10 of 264
Most frequent other events
EventArm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)
PERIPHERAL SENSORY NEUROPATHYNervous system disorders9/458/366/3527/37
CONSTIPATIONGastrointestinal disorders4/4511/369/3523/37
FATIGUEGeneral disorders9/4519/369/3520/37
NEUTROPHIL COUNT DECREASEDInvestigations3/4518/3618/3517/37
NAUSEAGastrointestinal disorders11/4516/3612/3519/37
BONE PAINMusculoskeletal and connective tissue disorders1/451/361/3519/37
ANEMIABlood and lymphatic system disorders3/459/366/3514/37
VOMITINGGastrointestinal disorders5/459/367/3514/37
RASH MACULO-PAPULARSkin and subcutaneous tissue disorders17/454/366/356/37
DYSPNEARespiratory, thoracic and mediastinal disorders6/4512/3610/358/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)Total
Median30 (18 to 69)33 (19 to 73)28 (18 to 64)32 (18 to 63)31 (18 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)Total
Female2218171875
Male2318181978
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)Total
Hispanic or Latino865120
Not Hispanic or Latino35292735126
Unknown or Not Reported21317
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)Total
American Indian or Alaska Native00000
Asian123410
Native Hawaiian or Other Pacific Islander00112
Black or African American31228
White33322329117
More than one race11002
Unknown or Not Reported706114
Region of Enrollment
Region of Enrollment(participants)Arm A (Brentuximab Vedotin, Nivolumab)Arm B1 (ABVD, Nivolumab) for Non-bulky PatientsArm B2 (ABVD, Nivolumab) for Bulky PatientsArm C (AVD, Brentuximab Vedotin, Nivolumab)Total
United States45363537153
08

Study locations

17 sites
09

References and documents

Publications

  • Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3. PubMed 40135712 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Nov 2024, 72 months.

Results were first posted in Oct 2026, 1 year 10 months after primary completion.

Of 180 non-industry phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 115. This study's 72 months is close to that.

Counting every sponsor, half of 203 studies reached it within 75 months; a quarter within 42 and three quarters within 111.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2024 → Nov 2024 and completion Dec 2024 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Oct 19, 2018
StartActual
Nov 28, 2018
Primary completionActual
Nov 30, 2024was Dec 2024
CompletionEst.
May 21, 2027was Dec 2024
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary completion
Dec 23, 2024→Nov 30, 2024 (actual)
Oct 29, 2026
Study completion
Dec 23, 2024→May 21, 2027
Oct 29, 2026
Enrollment
155→159
Oct 29, 2026
Interventions
Arm changed Group I Arm A (brentuximab vedotin, nivolumab)→Arm A (brentuximab vedotin, nivolumab); Group I Arm B (ABVD, nivolumab)→Arm B1 (ABVD, nivolumab) for non-bulky patients; Group II (AVD, brentuximab vedotin, nivolumab)→Arm C (AVD, brentuximab vedotin, nivolumab). Arms added: Arm B2 (ABVD, nivolumab) for bulky patients
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited18-month Progression-free survivalSurvival (PFS) for each armEach Arm of therapyTherapyTime frame: Up to 18 months
Oct 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40135712 ↗
Oct 29, 2026
Secondary outcomes
1 edited, 1 added, 4 removed
What changed in the outcomes
  • Edited32-year Progression-free Survival (PFS) for each armEach Arm of treatmentTherapyTime frame: Up to 3 years → Up to 2 years
  • AddedNumber of Patients Experiencing Grade 3-5 Adverse Events Related to Study TreatmentTime frame: Up to 4 years
  • RemovedIncidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0Time frame: Up to 3 years
  • RemovedScores from European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire C30, version 3 (EORTC-C30) for each arm of therapyTime frame: Up to 3 years
  • RemovedPositron emission tomography/computed tomography-2 negativity rateTime frame: After 2 courses of ABVD (each course is 28 days)
  • RemovedOverall survival for each arm of treatmentTime frame: Up to 3 years
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40135712 ↗
    Primary completion Dec 23, 2024→Nov 30, 2024 (now actual)
    Study completion Dec 23, 2024→May 21, 2027
    Enrollment 155→159
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited18-month Progression-free survivalSurvival (PFS) for each armEach Arm of therapyTherapyTime frame: Up to 18 months
    Secondary outcomes 1 edited, 1 added, 4 removed
    What changed in the outcomes
    • Edited32-year Progression-free Survival (PFS) for each armEach Arm of treatmentTherapyTime frame: Up to 3 years → Up to 2 years
    • AddedNumber of Patients Experiencing Grade 3-5 Adverse Events Related to Study TreatmentTime frame: Up to 4 years
    • RemovedIncidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0Time frame: Up to 3 years
    • RemovedScores from European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire C30, version 3 (EORTC-C30) for each arm of therapyTime frame: Up to 3 years
    • RemovedPositron emission tomography/computed tomography-2 negativity rateTime frame: After 2 courses of ABVD (each course is 28 days)
    • RemovedOverall survival for each arm of treatmentTime frame: Up to 3 years
    Interventions Arm changed Group I Arm A (brentuximab vedotin, nivolumab)→Arm A (brentuximab vedotin, nivolumab); Group I Arm B (ABVD, nivolumab)→Arm B1 (ABVD, nivolumab) for non-bulky patients; Group II (AVD, brentuximab vedotin, nivolumab)→Arm C (AVD, brentuximab vedotin, nivolumab). Arms added: Arm B2 (ABVD, nivolumab) for bulky patients
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03712202
Responsible party
Sponsor
First posted
Oct 19, 2018
Start date
Nov 28, 2018
Primary completion
Nov 30, 2024
Completion
May 21, 2027 (estimated)
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Alex F Herrera
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Dacarbazine · Doxorubicin · Nivolumab · Vinblastine

Start the discussion